Fubotv earnings beat by $0.10, revenue topped estimates
HONG KONG - HUTCHMED (China) Limited (Nasdaq/AIM:HCM; HKEX:13) announced Wednesday it has appointed Deutsche Bank AG (ETR:DBKGn), trading as Deutsche Numis, as its joint corporate broker in London with immediate effect.
The appointment follows the termination of HSBC Bank plc as joint corporate broker, according to a company statement. Panmure Liberum Limited and Cavendish Capital Markets Limited will continue to serve as joint corporate brokers in London, with Panmure Liberum also maintaining its role as HUTCHMED’s nominated advisor for AIM rules compliance.
HUTCHMED is a commercial-stage biopharmaceutical company focused on developing targeted therapies and immunotherapies for cancer and immunological diseases. The company has three medicines currently marketed in China, with one of these approved in multiple international markets including the United States, Europe and Japan.
The company maintains dual listings on Nasdaq and London’s AIM market, as well as a listing on the Hong Kong Stock Exchange.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.